UPB - Upstream Bio, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$33.00
DETAILS
HIGH:
$51.00
LOW:
$15.00
MEDIAN:
$33.00
CONSENSUS:
$33.00
UPSIDE:
294.27%
About Upstream Bio, Inc. (https://upstreambio.com)
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| E. Rand Sutherland | Chief Executive Officer & Director | 1970 | $1,001,750 USD |
| Aaron Deykin | Chief Medical Officer and Head of Research & Development | 1967 | $741,800 USD |
| Michael Paul Gray | Chief Financial Officer & Chief Operating Officer | 1971 | $706,300 USD |
| Allison Ambrose | Senior Vice President, General Counsel & Secretary | 1985 | $59,792 USD |
| Adam Houghton | Chief Business Officer | 1971 | – |
| Fang Xie | Vice President & Head of Biometrics | – | – |
| Lisa Fiering | Senior Vice President of People & Culture | – | – |
| Meggan Buckwell | Director of Corporate Communications & Investor Relations | – | – |
| Mersedeh Miraliakbari | Senior Vice President of Regulatory Affairs & Quality | – | – |
| Stacy Price | Chief Technology Officer | 1969 | – |